Trade Name: Angoron (available in Greece)
Amiodarone constitutes one of the most critical and potent antiarrhythmic agents. In addition to being classified as a Class III antiarrhythmic, it exhibits electrophysiological characteristics of Class I, II, and IV agents, which likely accounts for its superior therapeutic efficacy.
It can be administered both orally and intravenously. Amiodarone is highly lipophilic and, consequently, accumulates extensively in various peripheral tissues. This tissue accumulation is presumably responsible for its multi-organ adverse effect profile, with deposits localized in the liver, lungs, skin, and other organs. To achieve therapeutic and effective plasma concentrations for arrhythmia management, a loading dose regime (i.e., an initially higher dosing schedule) must be implemented until adequate tissue saturation is attained. Conversely, upon discontinuation, amiodarone exhibits prolonged elimination kinetics, maintaining its therapeutic activity for an additional 1 to 2 months. It can be administered with relative safety in patients with renal impairment, as its elimination pathway is predominantly hepatic. As a Class III antiarrhythmic agent, it prolongs the QT interval; however, the incidence of inducing torsades de pointes is exceedingly rare compared to other Class III antiarrhythmics.
Indications
- Amiodarone is indicated for the management of a broad spectrum of supraventricular and ventricular arrhythmias.
- Beyond its superior efficacy relative to alternative antiarrhythmics, its comparative clinical advantage lies in its feasibility for administration to patients with structural heart disease and concomitant heart failure.
- Amiodarone is highly suitable for preventing recurrent ventricular tachycardia in patients with underlying structural heart disease, including ischemic cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy. However, in cases of life-threatening ventricular tachyarrhythmias, it cannot substitute for implantable cardioverter-defibrillator (ICD) therapy. Thus, the ICD is implanted to terminate ventricular tachycardia episodes, whereas amiodarone is adjutantly prescribed to suppress and prevent their recurrence.
- It represents the most effective pharmacological agent for the rhythm control and prevention of atrial fibrillation recurrences; nonetheless, due to its frequent and severe adverse effect profile, it does not constitute a first-line therapeutic option, particularly in younger patient populations.
- It is highly effective in suppressing ventricular premature complexes (VPCs), both in patients with a structurally normal heart and those with structural cardiac disease. Nevertheless, identical clinical restrictions regarding its initiation apply due to its toxicity profile.
- It may be administered perioperatively in cardiac surgery to prevent post-operative atrial fibrillation.
Adverse Effects
Adverse events manifest in approximately 75% of patients undergoing long-term amiodarone therapy. These include:
- Thyroid dysfunction, predominantly presenting as hypothyroidism and less frequently as hyperthyroidism.
- Amiodarone-induced pulmonary toxicity, which can precipitate severe respiratory degradation and, in certain instances, progress to fatal outcomes.
- Hepatic disorders, initially manifesting as an asymptomatic elevation of serum transaminases (liver enzymes) and, in rare instances, advancing to hepatic cirrhosis.
- Blue-gray skin discoloration (amiodarone-induced pigmentation), particularly pronounced upon ultraviolet (sun) exposure.
- Ocular abnormalities; corneal microdeposits (cornea verticillata) occur in 100% of patients receiving amiodarone therapy for a duration exceeding six months.
- Gastrointestinal distress, such as nausea and constipation.
- Cardiovascular complications, including sinus bradycardia, atrioventricular (AV) block, and less frequently, the polymorphic ventricular tachycardia known as torsades de pointes.
In patients requiring mandatory long-term amiodarone administration, rigorous and regular laboratory monitoring is imperative for the early detection and management of these adverse effects. This surveillance regime must primarily comprise serial blood tests—specifically evaluating thyroid function and hepatic enzymes—alongside comprehensive pulmonary function assessments.